Similar to the results presented here, CD19‐targeting axicabtagene ciloleucel CAR‐T therapy responses were observed in patients with relapsed/refractory B‐cell NHL who had undetectable levels of CD19 in the phase 2 ZUMA‐1 clinical trial (NCT02348216), suggesting that CD19 expression levels did not impact response rates to or durable responses after axicabtagene ciloleucel; however, further investigations are necessary to understand better if and how risk of relapse could be increased in patients with a low CD19 copy number [20, 22, 24]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.